Pirfenidone is the only medicine approved worldwide for IPF.

Pirfenidone is marketed by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.

View Pipeline

ACTIMMUNE (Interferon gamma-1b)

For additional information on Actimmune® including full
prescribing information, please go to www.actimmune.com.

More about Actimmune®

ERS Research Award on IPF

Award for a young investigator. Application deadline for 2012: February 23, 2012. Learn More



Ascend Clinical Trial

For information on the ASCEND Phase 3 study of pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) please visit clinicaltrials.gov.

Events

January 11, 2012

InterMune at JPMorgan Global Healthcare Conference - Conference call and webcast

View Our Event Calendar

News

January 5, 2012

InterMune to Present at J. P. Morgan Healthcare Conference

January 5, 2012

InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights

View All Press Releases